Shape Memory Medical Secures $10M Note for Clinical Evidence Programs

Shape Memory Medical has secured $10 million in convertible-note financing to support two clinical evidence programs for its shape-memory polymer embolization technology.

August Global Partners led the financing. Taiwania Capital joined as a new investor, with additional support from HEAL Venture Lab.

The financing is a convertible note, not a priced equity round. The structure gives the company capital now while leaving some future ownership economics to be determined by the note's conversion terms.

A material designed to change inside the body

Shape Memory Medical has developed an embolic material that is compressed for delivery through a catheter and expands after it comes into contact with blood. The company is studying the platform across vascular conditions where physicians need to fill or obstruct a space inside the body.

The company reports that its technology has been used in more than 3,500 patients and has regulatory approvals in more than 40 countries. Those figures are company-reported and do not replace the evidence required for new indications or U.S. adoption.

The new capital will support patient follow-up and data collection for the AAA-SHAPE pivotal trial and help advance the FLAGSHIP first-in-human feasibility study in aortic dissection.

The AAA-SHAPE evidence program

Shape Memory Medical completed enrollment in the AAA-SHAPE trial in July 2026. The randomized study enrolled 180 patients across 48 centers in the United States, Europe, and New Zealand, with participants assigned in a 2:1 ratio.

The trial is evaluating the company's Impede-FX RapidFill device as an adjunct to endovascular aneurysm repair for abdominal aortic aneurysms. Patient follow-up is planned for five years.

Completing enrollment is a meaningful operational milestone. It is not the same as a successful clinical outcome. The company must still maintain follow-up, protect data quality, analyze the results, and show whether the treatment changes outcomes that matter to clinicians and regulators.

A second program in aortic dissection

The FLAGSHIP program is earlier. It is designed as a first-in-human feasibility study for aortic dissection, another condition in which the company believes its polymer platform may have value.

Running a pivotal follow-up program beside an early feasibility study creates two clocks. One is producing the evidence required to support a mature indication. The other is determining whether the platform can travel into a new one.

Convertible-note financing can bridge that period without forcing the company to price all of the future evidence today. It can also increase the importance of the next financing event if timelines stretch or the data arrives differently than expected.

The $10 million gives Shape Memory Medical more time to finish the record already underway and begin another. The material expands quickly. The evidence still has to move at the speed medicine allows.